ClinicalTrials.gg
Active, not recruitingNCT05409989Updated Nov 10, 2026

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

An interventional study of FRED™ X™ in Intracranial Aneurysm, sponsored by Microvention-Terumo, Inc.. Active, not recruiting at 23 sites in United States. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Microvention-Terumo, Inc. (part of Terumo Corporation) · Not applicable, Interventional, and Treatment

Updated Nov 10, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies in Intracranial Aneurysm by Terumo Corporation — 3 open to participants now, 7 under way, none of them phase 3. Intracranial Aneurysm · Terumo Corporation.

Started
2022
with 1 other
No phase
5 of 21
none open now
Registered
17th of 21
by date

Among the 21 studies in Intracranial Aneurysm by Terumo Corporation, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 17th registered.

Intracranial Aneurysm

418 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

3 of the 21 studies in Intracranial Aneurysm by Terumo Corporation are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 83 Intracranial Aneurysm studies recruiting now, 49 (59%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 22 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Intracranial Aneurysm by Terumo Corporation, or all of them as a file.
02

Study summary

The objective of this study is to generate contemporaneous clinical data to facilitate a reasonable comparison of the performance of the FRED™ X™ device with the performance of the FRED™ device. The data generated from this study will be compared to the safety and effectiveness of the FRED™ device by meeting the same performance goals (PGs) established for the FRED™ pivotal study.

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects for this study must meet ALL the following criteria:

  1. Subject has single target aneurysm in the internal carotid artery from petrous segment to the terminus of the internal carotid artery.
  2. The parent artery diameter must be 2.0 - 5.0 mm distal and/or proximal to the target intracranial aneurysm.
  3. Negative pregnancy test (serum or urine) in a female subject who has had menses in the last 18 months.
  4. Subject commits to return to the site for the 30- day, 6-month, 12-month, 2-year, 3-year, and 5-year follow-up evaluations.
  5. The subject or his/her authorized representative must sign the IRB-approved written form prior to the start of any study procedures.
  6. The subject has a modified Rankin Scale (mRS) ≤ 2.
  7. The subject has a wide-necked ( ≥4mm or dome-to-neck ratio \<2) saccular or fusiform aneurysm.

Exclusion criteria

Exclusion Criteria:

Subjects shall be excluded from the study if ANY of the following conditions exist:

  1. Subject who suffers from a subarachnoid hemorrhage in the last 60 days.
  2. Subject who suffers from intracranial hemorrhage in the last 30 days.
  3. Subject who presents with an intracranial mass or currently undergoing radiation therapy for carcinoma of the head or neck region.
  4. Subject with symptomatic extracranial or intracranial stenosis of the parent artery (>50%) proximal to the target aneurysm.
  5. Subject with an irreversible bleeding disorder, a count \< 100 x 103 cells/mm3 or known platelet dysfunction or a to or inability to tolerate anticoagulants/antiplatelet agents or thrombolytic drugs.
  6. Subject with history of major bleeding disorder (based on coagulation profile and platelet count) and/or subject presents with signs of active bleeding.
  7. Subject with known to any component of the treatment device that cannot be medically controlled.
  8. Subject with documented contrast allergy, or other condition that prohibits imaging.
  9. Evidence of active bacterial infection at the time of treatment.
  10. Presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, less than 30%.
  11. Subject with a pre-existing stent in place at the target aneurysm.
  12. Subject who is unable to complete the required follow-ups.
  13. Subject who is pregnant, breastfeeding, or of and unwilling to prevent pregnancy during their participation in the study.
  14. Subject has a serious or life-threatening comorbidity that could confound study results and/or prevent completion of 5-year followup.
  15. Subject is enrolled in another device or drug study in which participation could confound study results.
  16. Subject has absent femoral pulses or other condition preventing femoral access, or is planned to be treated using a radial access approach.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Other
    Flow Re-Direction Endoluminal Device X

    FRED™ X™ device

    Device: FRED™ X™

Interventions

  • DeviceFRED™ X™

    The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.

    Also known as: Flow Re-Direction Endoluminal Device X

06

What researchers measure

Primary outcomes

  1. Primary Safety Endpoint Part 1: Proportion of subjects that experience either Death or major stroke within 30 days post-procedure.

    Major stroke is defined as a new neurological event that persists for \>24 hours and results in a ≥4-point increase in the NIHSS score compared to baseline or compared to any subsequent lower score.

    Time frame: 30-days

  2. Primary Safety Endpoint Part 2: Proportion of subjects that experience neurological death or major ipsilateral stroke within 12 months post-procedure.

    A major ipsilateral stroke is defined as that occurring within the vascular distribution of the stented artery. Neurological death is defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a neurologic cause.

    Time frame: 12 months

  3. Primary Effectiveness Endpoint: The percent of subjects with (1) complete (100%) occlusion of the target aneurysm and ≤50% stenosis of the parent artery at the target IA, and (2) in whom an alternative treatment of the target IA had not been performed.

    (1) Complete (100%) occlusion of the target aneurysm is assessed utilizing the Raymond-Roy Scale (Raymond Roy Class 1) and ≤50% stenosis of the parent artery at the target IA), and in whom an alternative treatment of the target IA had not been performed. The study will utilize independent Core Laboratory to adjudicate all angiographic outcomes, including aneurysm occlusion status and parent artery stenosis. (2) Alternative treatment is defined as re-treatment of the target aneurysm with an alternative treatment modality including open repair, endovascular placement of an additional stent or treatment of in-stent stenosis.

    Time frame: 12 months

07

Study locations

23 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Apr 2027, 55 months after the start.

Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 55 months is above that.

Counting every sponsor, half of 104 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Apr 2027, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2022
First posted
Jun 8, 2022
StartActual
Sep 20, 2022
Primary completionEst.
Apr 2027was Apr 2026
CompletionEst.
May 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Apr 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Apr 2026→Apr 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05409989
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Sep 20, 2022
Primary completion
Apr 2027 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion